News

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

$19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding.

12/20/2024

Synaptogenix Announces $5.0 Million Financing

NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered Offering, the "Offering") of additional shares of Preferred Stock and unregistered common stock purchase warrants.

09/11/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Synaptogenix, Inc. (SNPX) a buy, sell, or hold?

Synaptogenix, Inc. (SNPX) can sell. Click on Rating Page for detail.

What is Synaptogenix, Inc.'s stock price?

The price of Synaptogenix, Inc. (SNPX) is 2.4 and it was updated on 2025-05-09 01:22:14.

Is Synaptogenix, Inc. (SNPX) overvalued or undervalued?

Currently Synaptogenix, Inc. (SNPX) is in undervalued.

News

From:

To:

News
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No. Thu, Jul. 18, 2024
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based therapeutics. As reported in the press on April 30, 2024, the DEA will move to reclassify cannabis from a Schedule I drug to a Schedule III under the Controlled Substance Act on recommendation by the U.S. Department of Health and Human Services. Tue, May. 07, 2024
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days. Wed, Apr. 24, 2024
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m. Wed, Apr. 03, 2024
Synaptogenix President Daniel L. Alkon, M.D. Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D. Tue, Dec. 19, 2023

SEC Filings

SEC Filings
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 04/07/2025
Synaptogenix, Inc. (SNPX) - 10-K - Current report SEC Filings 03/27/2025
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/20/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/06/2024
Synaptogenix, Inc. (SNPX) - DEFA14A SEC Filings 11/20/2024
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 11/12/2024
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 11/07/2024
Synaptogenix, Inc. (SNPX) - ARS SEC Filings 11/05/2024
Synaptogenix, Inc. (SNPX) - PRE 14A SEC Filings 10/28/2024
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 10/22/2024
Synaptogenix, Inc. (SNPX) - S-3 SEC Filings 10/10/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 10/04/2024
Synaptogenix, Inc. (SNPX) - D SEC Filings 09/23/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 09/13/2024
Synaptogenix, Inc. (SNPX) - 424B5 SEC Filings 09/12/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 09/11/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 09/09/2024
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 08/14/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 06/21/2024
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 05/15/2024
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 04/10/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 04/04/2024
Synaptogenix, Inc. (SNPX) - 10-K - Current report SEC Filings 04/01/2024
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 02/06/2024
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/21/2023
Synaptogenix, Inc. (SNPX) - ARS SEC Filings 11/14/2023
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 11/14/2023
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 11/13/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 11/06/2023
Synaptogenix, Inc. (SNPX) - PRE 14A SEC Filings 11/03/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 09/22/2023
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 07/19/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 06/22/2023
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 05/15/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 04/28/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 04/14/2023
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 03/31/2023
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 03/27/2023
Synaptogenix, Inc. (SNPX) - 10-K - Current report SEC Filings 03/21/2023
Synaptogenix, Inc. (SNPX) - PRE 14A SEC Filings 03/17/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 03/07/2023
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 02/17/2023
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 02/08/2023
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 01/18/2023
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 01/09/2023
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 12/28/2022
Synaptogenix, Inc. (SNPX) - PRE 14A SEC Filings 12/28/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/28/2022
Synaptogenix, Inc. (SNPX) - 424B3 SEC Filings 12/28/2022
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 12/20/2022
Synaptogenix, Inc. (SNPX) - S-3 SEC Filings 12/16/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/16/2022
Synaptogenix, Inc. (SNPX) - 4/A SEC Filings 12/01/2022
Synaptogenix, Inc. (SNPX) - S-8 SEC Filings 11/22/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 11/22/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 11/18/2022
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 11/17/2022
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 11/10/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 10/13/2022
Synaptogenix, Inc. (SNPX) - DEFA14A SEC Filings 08/25/2022
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 08/25/2022
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 08/16/2022
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 08/05/2022
Synaptogenix, Inc. (SNPX) - 4/A SEC Filings 06/23/2022
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 05/13/2022
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 04/28/2022
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 04/28/2022
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 04/25/2022
Synaptogenix, Inc. (SNPX) - UPLOAD SEC Filings 04/21/2022
Synaptogenix, Inc. (SNPX) - S-3 SEC Filings 04/15/2022
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 04/06/2022
Synaptogenix, Inc. (SNPX) - 10-K - Current report SEC Filings 03/29/2022
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 02/22/2022
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 02/11/2022
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 02/10/2022
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 01/31/2022
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 11/12/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 10/01/2021
Synaptogenix, Inc. (SNPX) - S-8 SEC Filings 08/13/2021
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 08/13/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 07/16/2021
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 07/15/2021
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 07/07/2021
Synaptogenix, Inc. (SNPX) - SC 13G SEC Filings 07/07/2021
Synaptogenix, Inc. (SNPX) - 424B3 SEC Filings 07/07/2021
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 07/06/2021
Synaptogenix, Inc. (SNPX) - S-1/A SEC Filings 07/02/2021
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 07/02/2021
Synaptogenix, Inc. (SNPX) - UPLOAD SEC Filings 07/01/2021
Synaptogenix, Inc. (SNPX) - D SEC Filings 06/29/2021
Synaptogenix, Inc. (SNPX) - SC 13G SEC Filings 06/25/2021
Synaptogenix, Inc. (SNPX) - S-1 SEC Filings 06/24/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 06/21/2021
Synaptogenix, Inc. (SNPX) - 3/A SEC Filings 06/17/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 06/16/2021
Synaptogenix, Inc. (SNPX) - 4 SEC Filings 06/16/2021
Synaptogenix, Inc. (SNPX) - 3 SEC Filings 06/14/2021
Synaptogenix, Inc. (SNPX) - CERT SEC Filings 06/07/2021
Synaptogenix, Inc. (SNPX) - 8-A12B SEC Filings 06/04/2021
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 05/14/2021
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 04/30/2021
Synaptogenix, Inc. (SNPX) - SC 13G SEC Filings 04/30/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 04/30/2021
Synaptogenix, Inc. (SNPX) - 424B3 SEC Filings 04/30/2021
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 04/29/2021
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 04/27/2021
Synaptogenix, Inc. (SNPX) - S-1/A SEC Filings 04/13/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 04/08/2021
Synaptogenix, Inc. (SNPX) - 10-K - Current report SEC Filings 03/30/2021
Synaptogenix, Inc. (SNPX) - DEF 14A SEC Filings 03/12/2021
Synaptogenix, Inc. (SNPX) - PRE 14A SEC Filings 03/01/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 02/17/2021
Synaptogenix, Inc. (SNPX) - SC 13G/A SEC Filings 02/12/2021
Synaptogenix, Inc. (SNPX) - D SEC Filings 02/12/2021
Synaptogenix, Inc. (SNPX) - S-1 SEC Filings 02/08/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 01/22/2021
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 01/19/2021
Synaptogenix, Inc. (SNPX) - 10-Q - Quarterly Report SEC Filings 12/23/2020
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/16/2020
Synaptogenix, Inc. (SNPX) - 8-K - Current report SEC Filings 12/10/2020
Synaptogenix, Inc. (SNPX) - 424B3 SEC Filings 11/20/2020
Synaptogenix, Inc. (SNPX) - 424B1 SEC Filings 11/12/2020
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 11/10/2020
Synaptogenix, Inc. (SNPX) - EFFECT SEC Filings 11/09/2020
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 11/06/2020
Synaptogenix, Inc. (SNPX) - S-1/A SEC Filings 11/05/2020
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 11/05/2020
Synaptogenix, Inc. (SNPX) - S-1/A SEC Filings 10/30/2020
Synaptogenix, Inc. (SNPX) - S-1 SEC Filings 10/09/2020
Synaptogenix, Inc. (SNPX) - CORRESP SEC Filings 10/09/2020
Synaptogenix, Inc. (SNPX) - UPLOAD SEC Filings 08/25/2020
Synaptogenix, Inc. (SNPX) - DRS SEC Filings 07/30/2020
Synaptogenix, Inc. (SNPX) - D SEC Filings 09/05/2013
Synaptogenix, Inc. (SNPX) - D SEC Filings 03/13/2013

Press Releases

StockPrice Release
Synaptogenix board of directors forms special committee to explore value creation opportunities utilizing balance sheet strength 12/20/2024
Synaptogenix announces $5.0 million financing 09/11/2024
Synaptogenix announces new collaboration with lsu health new orleans for study of proprietary analogs in spinal cord injury 07/18/2024
Synaptogenix applauds dea proposal to reclassify cannabis and shares expected benefits to cannasoul for cannabinoid-based drug discovery 05/07/2024
Synaptogenix regains compliance with nasdaq minimum bid price requirement for continued listing 04/24/2024
Synaptogenix announces reverse stock split to maintain nasdaq listing 04/03/2024
Synaptogenix president daniel l. alkon, m.d. 12/19/2023
Synaptogenix joins leading neuroscientists and academics as speaker at usc-sponsored forum on age-related diseases including alzheimer's 12/06/2023
Synaptogenix acquires significant stake in cannasoul analtyics ltd. co-founded by the technion - israel institute of technology 11/02/2023
Synaptogenix announces peer-reviewed publication of nih-sponsored phase 2 clinical trial results demonstrating safe, significant, and persistent benefits of bryostatin-1 in advanced alzheimer's disease 09/26/2023
Bryostatin-1 from synaptogenix shows statistically significant results as an als treatment in pre-clinical independent study 09/07/2023
Synaptogenix and cleveland clinic to submit investigational new drug (ind) application to fda for clinical trial of bryostatin-1 in multiple sclerosis 07/19/2023
Synaptogenix abstract highlighting bryostatin-1 benefits in severe alzheimer's disease accepted for presentation at 11th international brain research organization world congress of neuroscience 07/13/2023
Synaptogenix provides corporate update and outlines potential business opportunities 03/07/2023
Synaptogenix announces topline results from nih-sponsored phase 2 clinical trial of bryostatin-1 for advanced alzheimer's disease 12/16/2022
Synaptogenix welcomes lecanemab phase 3 trial results 09/28/2022
Synaptogenix announces live appearance of its president and cso on streaming financial news network 08/12/2022
Synaptogenix announces changes to scientific advisory board in preparation for phase 2 data 07/26/2022
Synaptogenix announces corporate update conference call 07/21/2022
Synaptogenix advances dosing of first patient in dose optimization clinical trial in preparation for nih-sponsored, phase 2 alzheimer's disease trial data 07/20/2022
Synaptogenix completes patient enrollment in nih sponsored phase 2b alzheimer's disease trial 04/19/2022
New peer reviewed article demonstrates extended therapeutic potential of synaptogenix's bryostatin for alzheimer's disease 04/05/2022
Synaptogenix to present at hanson wade 10th annual neurodegenerative drug development summit 03/29/2022
Synaptogenix to present at sachs 5th annual neuroscience innovation forum 03/22/2022
Synaptogenix to present research highlighting potential broad applicability for lead compound bryostatin at the international conference on alzheimer's and parkinson's diseases (ad/pd 2022) 03/15/2022
Synaptogenix moves forward with clinical development plans for bryostatin-1 as a treatment for multiple sclerosis 02/23/2022
Synaptogenix announces publication of peer-reviewed scientific article evidencing byrostatin-1's improved cognition over baseline in advanced alzheimer's disease patients 02/01/2022
Synaptogenix announces participation at the h.c. wainwright 23rd annual global investment conference 09/10/2021
Synaptogenix signs memorandum of understanding with nemours a.i. dupont hospital to initiate trial using bryostatin, under orphan drug status, to treat fragile x syndrome 08/05/2021
Synaptogenix discloses positive results of further bryostatin trial analyses in presentation at alzheimer's association international conference 2021 07/26/2021
Synaptogenix announces conference call to discuss aaic abstract findings 07/21/2021
Synaptogenix to present data at alzheimer's association international conference 2021 highlighting bryostatin restores cognitive function above baseline 07/14/2021
Synaptogenix announces regenerative patent award to treat alzheimer's disease 07/07/2021
Synaptogenix announces live appearance of its president and cso on streaming financial news network 06/24/2021
Synaptogenix announces $12.5 million private placement 06/14/2021
Synaptogenix announces phase 2b nih sponsored alzheimer's disease trial update 06/09/2021
Synaptogenix responds to fda approval of aducanumab 06/07/2021
Synaptogenix announces plan to uplist on the nasdaq stock market 05/19/2021

More Headlines

News
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders. 12/06/2023
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications Partners to drive development and commercialization of Cannasoul Analytics' intellectual property and technologies licensed from The Technion - Israel Institute of Technology NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with Cannasoul Analytics Ltd. ("Cannasoul") in support of research and development of pharmaceutical therapeutics. 11/02/2023
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed Phase 2 trial of Bryostatin-1 for Alzheimer's disease. 09/26/2023
Best Penny Stocks To Buy Now? 10 Under $1 To Watch Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns. 09/13/2023
Best Penny Stocks To Buy Now? 7 Under $1 To Watch Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to traditional blue chip stocks. 09/11/2023
Best Penny Stocks To Buy Now? 3 Under $1 To Watch Penny stocks, typically priced below $5, have become a popular choice for day traders due to their potential for rapid gains. These stocks can offer market-beating returns in a short period, making them attractive for those looking for quick profits. 09/07/2023
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p 09/07/2023
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK , July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it entered into an agreement with Cleveland Clinic to conduct a phase 1 trial of Bryostatin-1 in multiple sclerosis (MS). Cleveland Clinic will manage the clinical trial's implementation, including an Investigational New Drug (IND) submission to the US Food and Drug Administration and patient enrollment. 07/19/2023
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation NEW YORK , July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that an abstract featuring secondary endpoint data of its National Institutes of Health (NIH) sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization (IBRO) World Congress of Neuroscience to be held in September 2023 in Spain. In the recently completed Phase 2 clinical trial of Bryostatin-1, two cohorts were studied: a Moderate Cohort, with MMSE* scores of 15-18, and a Severe Cohort, with MMSE scores of 10-14. 07/13/2023
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today? Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the treatment of advanced Alzheimer's disease, SNPX stock dropped 70% on Friday morning, extending losses to around 74% in the late afternoon. 12/16/2022
Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action. 12/09/2022
Synaptogenix Announces Corporate Update Conference Call NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26 th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. 07/21/2022
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29 th at 2pm ET. The presentation is entitled, "Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration. 03/29/2022
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present a "Spotlight Showcase" of Synaptogenix under the title "Regenerative Therapeutics" on Tuesday, March 22nd at 8am ET. "Recently reported consolidated results of Synaptogenix Phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric Severe Impairment Battery (SIB) scores, over baseline, in a placebo-controlled publication on Bryostatin for advanced AD patients (Thompson, Tuchman, and Alkon, Journal Alzheimer's disease). 03/22/2022
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) NEW YORK , March 15, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present recent clinical results today, Tuesday, March 15 th, at the International Conference on Alzheimer's (AD) and Parkinson's Diseases (AD/PD 2022). The titled abstract, "Neurotrophic Restoration for Neurodegenerative Disease" summarizes therapeutic improvement by Bryostatin for advanced AD patients in placebo-controlled trials and its potential benefits for other neurodegenerative disorders such as Parkinson's Disease. 03/15/2022
Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment SNPX did not achieve primary endpoints in two Phase 2 studies for Bryostatin for the treatment of Alzheimer's Disease in moderately severe to severe patients. Post-hoc analysis of 95 patients from these two studies with MMSE 10-15, and not taking Namenda, revealed a statistically significant improvement vs placebo. 11/16/2021
5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when a heavily shorted stock rises in value instead of falling. 11/15/2021
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds. 10/05/2021
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Synaptogenix, Inc (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced it will be featured as a presenting company at the H.C. 09/10/2021
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it signed a memorandum of understanding ("MOU") with the Nemours A.I. DuPont Hospital for Children, an internationally recognized leader in the comprehensive care of childhood diseases, with the intention of initiating a trial to treat Fragile X with Bryostatin. 08/05/2021
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients. 07/26/2021
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings NEW YORK, July 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will hold a conference call for investors to discuss its abstract presented at the Alzheimer's Association International Conference. The call will take place on Monday, July 26 th at 4:15pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. 07/21/2021
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline NEW YORK, July 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract has been accepted at the Alzheimer's Association International Conference ("AAIC"), which will be held online and in-person July 26-30, 2021. The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy. 07/14/2021
Synaptogenix: The Next Big Thing In Alzheimer's The company's Bryostatin drug is likely to read out positive data in current phase 2, despite its checkered past. 06/16/2021
Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD). To date, the Company has dosed 58 of its target 100 patients. 06/09/2021
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD"). To date, the Company has now dosed 58 of its target 100 patients. 06/09/2021
Synaptogenix Responds to FDA Approval of Aducanumab NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new Alzheimer's treatment Aducanumab. Daniel Alkon, M.D. 06/07/2021

Unlock

SNPX Ratings Summary

SNPX Quant Ranking